Clinical Trials for Inhibrx Biosciences

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Inhibrx Biosciences

Clinical Trials (5)

NCT06353997
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
PHASE2Recruiting
12 participants
Started: Sep 5, 2024 · Completed: Jun 30, 2029
1 condition2 sponsors4 locations
NCT06295731
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
PHASE2/PHASE3Recruiting
410 participants
Started: May 14, 2024 · Completed: May 31, 2029
1 condition1 sponsor78 locations
NCT04950075
Study of INBRX-109 in Conventional Chondrosarcoma
PHASE2Recruiting
201 participants
Started: Sep 23, 2021 · Completed: Dec 31, 2026
1 condition1 sponsor58 locations
NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
PHASE1/PHASE2Recruiting
333 participants
Started: Dec 10, 2019 · Completed: May 12, 2027
7 conditions2 sponsors42 locations
NCT03715933
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
PHASE1Recruiting
321 participants
Started: Oct 10, 2018 · Completed: Dec 31, 2026
2 conditions1 sponsor34 locations